Edwards Lifesciences Corporation
Edwards Lifesciences Corporation (EW) Revenue
Annual & quarterly revenue history · segment & region breakdown
EW · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsEdwards Lifesciences Corporation trailing twelve-month (TTM) revenue is $6.30B, an increase of 11.55% year-over-year from $6.07B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $6.07B | +$0.63B | +11.55% |
| 2024-12-31 | $5.44B | +$0.43B | +8.57% |
| 2023-12-31 | $5.01B | -$0.37B | -6.92% |
| 2022-12-31 | $5.38B | +$0.15B | +2.86% |
| 2021-12-31 | $5.23B | +$0.85B | +19.29% |
| 2020-12-31 | $4.39B | +$0.04B | +0.88% |
| 2019-12-31 | $4.35B | +$0.63B | +16.79% |
| 2018-12-31 | $3.72B | +$0.29B | +8.37% |
| 2017-12-31 | $3.44B | +$0.47B | +15.91% |
| 2016-12-31 | $2.96B | +$0.47B | +18.85% |
Compare revenue vs peers
Medical - DevicesCompare EW revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Edwards Lifesciences Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Edwards Lifesciences Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Edwards Lifesciences Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EW revenue · 4 questionsEW's trailing twelve-month (TTM) revenue is $6.30B. That is an increase of 11.55% year-over-year from $6.07B in FY2025.
▸ Source: FMP · Edwards Lifesciences Corporation SEC filings · GAAP · Edwards Lifesciences Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026